Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:39 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Bone Loss Treatment From Adjuvant Zoledronate Efficacy
NCT01623908 · First Affiliated Hospital, Sun Yat-Sen University · NA · terminated · last registry update 2021-06-22 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, First Affiliated Hospital, Sun Yat-Sen University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FDPS in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-05-27Also stopped (terminated): University of Leeds, zoledronic acid (NCT00458796)
- 2022-02-25Results posted on the registry: M.D. Anderson Cancer Center, Dasatinib + Zoledronic Acid (NCT00566618)
- 2021-12-21Phase 3 first posted: Assiut University, Zoledronic Acid 4 MG (NCT05164952)
- 2020-10-22Also stopped (terminated): University of Wisconsin, Madison, Alendronate (NCT02781805)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision